Mehdi Lahmar, MD (he/him/his)

Clinical Program Leader
Boehringer Ingelheim International GmbH, Germany

MD/PhD with 20 years experience in drug discovery and development across Biotech/Pharma companies and different therapeutic areas with assets at different stages of development. Worked in a multifunctionnal and mutlicultural environment. Joined BI 4 years ago to lead the clinical development for the MDM2 asset in oncology and based in Germany.

Poster(s):

• (P 185) LONGITUDINAL MUTATIONAL ANALYSIS OF TP53 IN CIRCULATING TUMOR DNA IN THE PLASMA OF PATIENTS WITH LIPOSARCOMA IN A PHASE I STUDY OF BRIGIMADLIN (BI 907828), AN MDM2-P53 ANTAGONIST

• (P 408) CHANGES IN COMPUTED TOMOGRAPHY FEATURES INDUCED BY BRIGIMADLIN (BI 907828) IN PATIENTS WITH LIPOSARCOMA: INSIGHTS FROM PHASE I STUDIES